ArticleInnovation (Cambridge (Mass.))2024

IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinoma.

Chuanliang Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.